Using aminoglycosides to treat sepsis in patients with kidney issues
Official title: Aminoglycoside Administration in Septic Patients
Run by University of Thessaly · NCT06226441 · Data updated 2026-11-12
This study is testing if a specific type of antibiotic can safely help patients with kidney problems who have sepsis or septic shock.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | University of Thessaly Academic / other |
| Locations | 1 site (Larissa, Thessaly) |
| Status | Recruiting |
| Started | June 2, 2023 |
| Main results expected | December 2025 |
| Study ends | December 2026 |
| Registry record updated | January 26, 2024 |
| Trial ID | NCT06226441 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults over 18 years old diagnosed with sepsis or septic shock and having a GFR of less than 40 ml/min.
✕Probably not a fit
Patients with known allergies to aminoglycosides or infections caused by strains resistant to these antibiotics may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial investigates the use of aminoglycosides, a class of antibiotics, in patients suffering from sepsis or septic shock, particularly those with impaired kidney function. The study aims to address the challenges of administering these antibiotics effectively while minimizing nephrotoxicity, which is a common concern in critically ill patients. By focusing on the pharmacokinetics of aminoglycosides in this population, the trial seeks to optimize dosing strategies to improve patient outcomes. Participants will receive continuous renal replacement therapy to manage their renal function during treatment.
Why it matters
Potential benefit: If successful, this approach could enhance the effectiveness of aminoglycosides in treating sepsis while reducing the risk of kidney damage.
How similar studies have gone: Other studies have shown promise in using aminoglycosides for treating multidrug-resistant infections, but this specific approach in septic patients with renal impairment is less explored.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * age \>18 years * diagnosis of sepsis or septic shock based on established criteria (Sepsis-3) 29 * patients with GFR \<40 ml/min * microbiemia from a Gram-negative microorganism and for which the attending physician decides to receive an aminoglycoside or sepsis/septic shock for which it is decided to administer it * signed consent of the patients' next of kin Exclusion Criteria: * absence of consent * known allergic reaction to aminoglycosides * infection from strains resistant to aminoglycosides. As long as the patient has received an aminoglycoside (empirical regimen) and the antibiogram follows it, the treatment can be modified based on the judgment of the attending physician, but the patient's data for the time he received the treatment under consideration are recorded and evaluated * unattainable placement of a central venous line for renal replacement therapy
Where it's running
-
Intensive Care Unit, University Hospiatl of Larissa
Larissa, Thessaly, Greece Recruiting
Study contacts
- Principal investigator: Epaminondas Zakynthinos, Prof — University Hospital of Larissa, Intensive Care Unit
- Study coordinator: Kyriaki Parisi, MD
- Email: kyriakiparisi@yahoo.com
- Phone: 00306948176845
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Non-invasive hemodynamic guidance for sepsis care on medical wards
This trial tests whether guiding fluid and vasopressor therapy for sepsis using non-invasive hemodynamic measurements works better than standard care.
-
Personalized Fluid Resuscitation in the Emergency Department
This pilot test checks if a quick, non-invasive stroke-volume assessment can help ED doctors tailor IV fluids for septic patients with low blood pressure.
-
Discordance between capillary refill time and oxygen use in septic shock
This study tests whether some septic shock patients can have a normal capillary refill time but still lack tissue oxygen use, to see if that mismatch relates to 28-day survival.
-
Targeting upper-normal magnesium to see if norepinephrine needs drop in septic shock
This trial tests whether keeping magnesium levels at the upper end of normal can reduce the amount and duration of norepinephrine needed in adults with septic shock.
-
Cortisol Levels and Mortality in Septic Shock ICU Patients
This study tests whether cortisol levels can predict death or recovery in adults with sepsis or septic shock in the ICU.
-
oXiris hemofilter use for adults with septic shock and kidney failure
This study tests whether using the oXiris hemofilter during continuous dialysis helps adults with septic shock and acute kidney injury survive and stabilize faster.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.